We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Charles River Laboratories

News List

Charles River Laboratories generates $824 million in first quarter europeanpharmaceuticalreview
May 07, 2021
Charles River Laboratories International’s first quarter revenue was approximately 17 percent higher in Q1 2021, with organic revenue growth of 13 percent.
Charles River Laboratories wraps up $380m acquisition of HemaCare pharmaceutical-business-review
January 09, 2020
Charles River Laboratories International has wrapped up its $380m acquisition of HemaCare, a California-based human-derived cellular products provider for the cell therapy market.
Charles River Laboratories to buy HemaCare for $380m pharmaceutical-business-review
December 20, 2019
Charles River Laboratories International has agreed to acquire human-derived cellular products provider HemaCare for around $380m in cash.
Charles River Laboratories Announces Refinancing of Credit Facilities and Offering of $500 Million of Senior Notes biospace
March 27, 2018
Charles River Laboratories International, Inc. today announced that the company has refinanced its existing $1 billion revolving credit facility in 2021.